Experimental Labour—offshoring Clinical Trials to China

References

• Anagnost A. S. (2006). Strange circulations: The blood economy in rural China. Economy and Society, 35(4), 509–529.
   Web of Science ®Google Scholar
• Anderson D. L. (2007). International patient recruitment: Regulatory guidelines, customs and practices. Dallas, TX: D. L. Anderson International Publishing.
   Google Scholar
• Ashish A. Gambardella A. (1994). The changing technology of technological change: General and abstract knowledge and the division of innovative labour. Research Policy, 23, 523–532.
   Web of Science ®Google Scholar
• Bailey W. Cruickshank C. Sharma N. (2007). Make your move: Taking clinical trials to the best location. http://www.atkearney.com/main.taf?p=5,1,1,116,3,1. Consulted March 2007.
   Google Scholar
• Berton E. (2006). More chinese get free drugs in clinical trials. Wall Street Journal Online, February 14. http://online.wsj.com/public/article/SB113988758015373215-3cIaQCU2VMtRObREr8e5R-j8AiP8_20060221.html. Accessed May 2007.
   Google Scholar
• Blumenthal D. Hsiao W. (2005). Privatization and its discontents—The evolving chinese health care system. New England Journal of Medicine, 353, 1165–1170.
   PubMed Web of Science ®Google Scholar
• Chigwedere E. (2006). How much are we reporting about ethical misconduct: A critical review of Cyranowski's article `Chinese Clinical Trials: Consenting adults? Not necessarily'. In Medical humanities report. Winter http:www.bioethics.msu.edu/mhr/06w/Ethical%20Misconduct.htm. Consulted March 2008.
   Google Scholar
• Code of Federal Regulations 21, part 50, 44, `Restrictions on clinical investigations involving prisoners.'
   Google Scholar
• Cooper M. Waldby C. (2008). Clinical labour: Donors and research subjects in the bioeconomy. Unpublished manuscript.
   Google Scholar
• Cyranowski D. (2005). Consenting adults? Not necessarily...' Nature, 435, 138–139.
   Web of Science ®Google Scholar
• Dosi G. Mazzucato M. (2006). Introduction. In Dosi G. Mazzucato M. (Eds.), Knowledge accumulation and industry evolution: The case of pharma-biotech (pp. 1–18). Cambridge: Cambridge University Press.
   Google Scholar
• Dutton M. R. (2004). Streetlife China. New York and London: Routledge.
   Google Scholar
• Epstein S. (2007). Inclusion: The politics of difference in medical research. Chicago: The University of Chicago Press.
   Google Scholar
• Ernst & Young (2006). Progressions 2006: Capturing global advantage in the pharmaceutical industry. New York: Ernst and Young Global Pharmaceutical Centre.
   Google Scholar
• Fisher J. A. (2007). Coming soon to a physician near you: Medical neoliberalism and pharmaceutical clinical trials. Harvard Health Policy Review, 8(1), 46–55.
   Google Scholar
• Gambardella A. (1995). Science and innovation in the US pharmaceutical industry. Cambridge: Cambridge University Press.
   Google Scholar
• Goodall S. Jannsens B. Wagner K. Wong J. Woods W. Yeh M. (2006). The promise of the east: India and China as R&D options. Nature Biotechnology, 24(9), 1061–1064.
   PubMed Web of Science ®Google Scholar
• Greenalgh S. Winkler E. A. (2005). Governing China's population: From leninist to neoliberal biopolitics. Stanford, CA: Stanford University Press.
   Google Scholar
• Hornblum A. M. (1998). Acres of skin: Human experiments in Holmesburg prison. New York and London: Routledge.
   Google Scholar
• Humphries M. Niese D. Dai P. (2006). China as a growing research base for innovation in medicines development. International Journal of Pharmaceutical Medicine, 20(6), 355–359.
   Google Scholar
• Jia H. (2005). China beckons to clinical trial sponsors. Nature Biotechnology, 23, 768.
   Web of Science ®Google Scholar
• Kearney A. T. ( Consulting Group) (2006). Fishing for opportunities: Successful clinical trials management. Pharmaceutical executive, June 1. http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=333301. Consulted March 2007.
   Google Scholar
• Krohn W. Weyer J. (1994). Real life experiments—society as a laboratory: The social risks of experimental research. Science and Public Policy, 21(3), 173–183.
   Google Scholar
• Lazzarato M. (2002). Puissances de l'invention: La psychologie economique de Gabriel Tarde contre l'economie politique. Paris: Les empecheurs de penser en rond.
   Google Scholar
• Mirowski P. Van Horn R. (2005). The contract research organization and the commercialization of scientific research. Social Studies of Science, 35(4), 503–548.
   PubMed Web of Science ®Google Scholar
• Morioka J. (2006). Clinical trials in China: Today and tomorrow. Contract Services Europe 1, 20–22 (May).
   Google Scholar
• Nightingale P. Mahdi S. (2006). The evolution in pharmaceutical innovation. In Dosi G. Mazzucato M. (Eds.), Knowledge accumulation and industry evolution: The case of pharma-biotech (pp. 73–111). Cambridge: Cambridge University Press.
   Google Scholar
• Ong A. (2007). Neoliberalism as exception: Mutations in citizenship and sovereignty. Durham: Duke University Press.
   Google Scholar
• Petryna A. (2006). Globalizing human subjects research. In Petryna A. Lakoff A. Kleinman A. (Eds.), Global pharmaceuticals: Ethics, markets, practices (pp. 33–60). Durham: Duke University Press.
   Google Scholar
• Petryna A. (2007). Clinical trials offshored: On private sector science and public health. BioSocieties, 2, 21–40.
   Google Scholar
• Pisano G. P. (2006). Science business: The promise, the reality, and the future of biotech. Boston, MA: Harvard Business School Press.
   Google Scholar
• Reid R. G. B. (2007). Biological emergences: Evolution by natural experiment. London: MIT Press.
   Google Scholar
• Rheinberger H.-J. (1997). Experimental complexity in biology: Some epistemological and historical remarks. Philosophy of Science, 64(Supplement), S245–S254 (December).
   Google Scholar
• Ross A. (2006). Fast boat to China: Corporate flight and the consequences of free trade; Lessons from Shanghai. New York: Pantheon.
   Google Scholar
• Salter B. Cooper M. Dickins A. (2006). China and the global stem cell bioeconomy: An emerging political strategy? Regenerative Medicine, 1(5), 671–683.
   PubMed Web of Science ®Google Scholar
• Salter B. Cooper M. Dickins A. Cardo V. (2007). Stem cell science in India: Emerging economies and the politics of globalisation. Regenerative Medicine, 2(1), 75–89.
   PubMed Web of Science ®Google Scholar
• Sassen S. (2003). Global cities and survival circuits. In Ehrenreich B. Hothschild A. (Eds), Global woman: Nannies, maids and sex workers in the new economy. London: Granta Books.
   Google Scholar
• Sharma S. (2004). Remembering SARS in Beijing: The nationalist appropriation of an epidemic. Sarai Reader, 4, 332–339.
   Google Scholar
• Shuchman M. (2007). Commercializing clinical trials—risks and benefits of the CRO boom. The New England Journal of Medicine, 357(14), 1365–1368.
   PubMed Web of Science ®Google Scholar
• Sunder Rajan K. (2006). Biocapital—the constitution of postgenomic life. Durham: Duke University Press.
   Google Scholar
• Sunder Rajan K. (2007). Experimental values: Indian clinical trials and surplus health. New Left Review, 45, 67–78 (May–June).
   Google Scholar
• Thiers F. A. Sinskey A. J. Berndt E. R. (2008). Trends in the globalization of clinical trials. Nature Reviews Drug Discovery, 7, 13–14 (January).
   Web of Science ®Google Scholar
• Thomas Scott C. Baker M. (2007). Overhauling clinical trials. Nature Biotechnology, 25(3), 287–292.
   Web of Science ®Google Scholar
• Thomke S. von Hippel E. Franke R. (1998). Modes of experimentation: An innovation process—and competitive—variable. Research Policy, 27, 315–332.
   Web of Science ®Google Scholar
• Thomson CenterWatch . (2007). State of the clinical trials industry: A sourcebook of charts and statistics. Boston: Thomson CenterWatch.
   Google Scholar
• Vaidya A. Anastasia L. Kermani F. (2007). The chinese biotechnology, life science and pharmaceutical industry (UK trade and investment life sciences sector group). London: UK Trade and Investment.
   Google Scholar
• Vastag B. (2006). New clinical trials policy at FDA. Nature Biotechnology, 24(9), 1043.
   Web of Science ®Google Scholar
• Waldby C. Cooper M. (2008). Post-fordist biotechnology and women's clinical labour. Australian Feminist Studies, 23(55), 57–73.
   Web of Science ®Google Scholar
• Watts J. (2007). Chinese hospital staff face attacks amid high prices and dubious care. The Guardian (12 May).
   Google Scholar
• Xu J. Li B. Qiang M. Liu H. Cong Y. (2006). Human subjects protections in clinical drug trials in China: A focus on the institute level. International Journal of Pharmaceutical Medicine, 20(6), 367–372.
   Google Scholar